Testing Experimental Medication in Healthy Subjects
common.study.values.description
“A Study of the Effects of LY3372689 on the Brain in Healthy Participants”
This study uses imaging to evaluate how LY3372689 binds to a protein in the brain. This study will be conducted in healthy participants and will last up to approximately 25 days after enrollment. Screening must be completed within 28 days prior to enrollment.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-no
Drug - LY3372689
Administered orally.
Diagnostic Test - [18F]LSN3316612
Administered IV.
participant.views.study.view.additional
participant.views.study.view.scientific-title
Assessment of Brain O-GlcNAcase (OGA) Enzyme Occupancy After Single Oral Doses of LY3372689 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]LSN3316612 in Healthy Subjects
common.study.values.clinical-trial-id
NCT03944031
participant.views.study.view.id
dwpvre
